Hydrogel Organoids to study B cell receptor inhibitors in African-American lymphoma
Official title: Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
Funded at Georgia Institute of Technology · NIH-11379137 · Data updated 2026-11-12
This grant tests a patient-focused approach to understand how B cell signaling drives certain lymphomas in African-American patients and how targeted drugs might work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $546,993 |
| NIH project number | 5R01CA266052-05 |
| Project ID | NIH-11379137 on NIH RePORTER |
Who could benefit from this research
✓Could help
African-American patients or those with African ancestry affected by non-Hodgkin lymphoma, including DLBCL and MZL subtypes, may benefit from future translational applications.
✕Less likely to help
Patients without these specific lymphoma subtypes or ancestry factors may not directly benefit from this basic-to-translational study.
What this research studies
Researchers are using hydrogel-based organoids derived from African-American lymphoma biology to model B cell receptor signaling and test inhibitors that could be effective against aggressive DLBCL and certain MZLs. The project aims to connect genetic ancestry, tumor biology, and treatment response to identify potential strategies for these patients. By recreating tumor environments in the lab, scientists can observe how B cell pathways react to inhibitors and how outcomes might differ by ancestry. The work could inform future personalized therapies and help reduce disparities in lymphoma treatment outcomes.
Why it matters
Potential benefit: If successful, the work could lead to more effective, tailored therapies for African-American lymphoma patients and help reduce survival disparities.
How similar studies have gone: Previous work has shown that tumor organoids can model drug responses, but applying this to AA-DLBCL and B cell receptor inhibitors is still emerging.
Where this research is happening
-
Georgia Institute of Technology
Atlanta, United States Active
Researchers
- Principal investigator: Singh, Ankur — Georgia Institute of Technology
- Study coordinator: Singh, Ankur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.